Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-715 · 1 trial · 1 indication
Dose limiting toxicities are defined as ALLO-715-related adverse events with onset within 28 days following infusion of ALLO-715.
The proportion of subjects in a dose cohort with DLTs of ALLO-647
Dose limiting toxicities are defined as ALLO-715-related adverse events with onset within 28 days following infusion of ALLO-715.
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-715, Nirogacestat | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-715 | GENETIC | ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
| Nirogacestat | DRUG | a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells. |
Inclusion Criteria: * Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (serum, urine, or free light chain \[FLC\]) per International Myeloma Working Group (IMWG) criteria * At least 3 prior lines of MM therapy, including a proteasome inhibitor, immunomodulat...
Top 20 of 25 competitors
ALLO-715 is an investigational allogeneic CAR T cell therapy being studied for the treatment of relapsed or refractory multiple myeloma. It is a gene therapy developed by Allogene Therapeutics, Inc. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
ALLO-715 targets BCMA, or B-cell maturation antigen, which is expressed on multiple myeloma cells. As an allogeneic CAR T cell therapy, it is designed to recognize and attack BCMA-positive cancer cells. This mechanism is being evaluated in the Phase 1 UNIVERSAL clinical trial.
ALLO-715 is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALLO. The company is conducting clinical research on this investigational therapy for relapsed or refractory multiple myeloma.
ALLO-715 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial, known as UNIVERSAL, has been completed, and the drug has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
ALLO-715 is being studied in the UNIVERSAL trial, registered as NCT04093596. This Phase 1 study evaluated the safety and efficacy of ALLO-715 in adults with relapsed or refractory multiple myeloma. The trial enrolled 73 participants in the United States and has been completed.
ALLO-715 is an allogeneic CAR T cell therapy that targets BCMA, making it a BCMA-directed CAR T therapy. It is being developed for relapsed or refractory multiple myeloma. The drug is distinct from other BCMA CAR T therapies due to its allogeneic, or off-the-shelf, approach.